Relacorilant ( Lifyorli – Corcept Therapeutics), an oral first-in-class glucocorticoid receptor antagonist, has been approved by the FDA for use in combination with nab-paclitaxel ( Abraxane , and generics)…
Med Lett Drugs Ther. 2026 May 11; 68(1754):e79-80 doi:10.58347/tml.2026.1754f
Relacorilant ( Lifyorli – Corcept Therapeutics), an oral first-in-class glucocorticoid receptor antagonist, has been approved by the FDA for use in combination with nab-paclitaxel ( Abraxane , and generics) for treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who received 1-3 prior lines of systemic therapy, one of which included bevacizumab ( Avastin , and others).
Avmapki Fakzynja Co-Pack (Verastem), a combination of the kinase inhibitors avutometinib and defactinib, has received accelerated approval from the FDA for treatment of KRAS-mutated recurrent low-grade serous…
Med Lett Drugs Ther. 2025 Jul 21; 67(1733):e120-1 doi:10.58347/tml.2025.1733j
Avmapki Fakzynja Co-Pack (Verastem), a combination of the kinase inhibitors avutometinib and defactinib, has received accelerated approval from the FDA for treatment of KRAS-mutated recurrent low-grade serous ovarian cancer in women who had previously received systemic therapy. Neither drug is approved for use as monotherapy for any indication. Avmapki Fakzynja is the first treatment to be approved in the US for this indication.
Mirvetuximab soravtansine-gynx ( Elahere – Immuno-Gen), an antibody-drug conjugate, has received accelerated approval by the FDA for treatment of folate receptor (FR) alpha-positive, platinum-resistant…
Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e205-6
Mirvetuximab soravtansine-gynx ( Elahere – Immuno-Gen), an antibody-drug conjugate, has received accelerated approval by the FDA for treatment of folate receptor (FR) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who received 1-3 prior lines of systemic therapy. Accelerated approval was based on the overall response rate and median duration of response.
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib ( Lynparza – AstraZeneca), niraparib ( Zejula – Tesaro),…
Med Lett Drugs Ther. 2017 Dec 4; 59(1535):200-2
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib ( Lynparza – AstraZeneca), niraparib ( Zejula – Tesaro), and rucaparib ( Rubraca – Clovis) are each approved for somewhat different indications and for patients with different biomarkers (see Table 2).
The FDA has approved the oral poly (ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – Astra-Zeneca) as monotherapy for treatment of women with advanced ovarian cancer who have BRCA1/2 germline…
Med Lett Drugs Ther. 2016 Feb 29; 58(1489):e32-3
The FDA has approved the oral poly (ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – Astra-Zeneca) as monotherapy for treatment of women with advanced ovarian cancer who have BRCA1/2 germline mutations and have received at least 3 prior lines of chemotherapy. Olaparib is the first PARP inhibitor to be approved in the US. It is approved outside the US for maintenance treatment of relapsed BRCA-mutated ovarian cancer.
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec; 10(124):87-94
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer.…
Med Lett Drugs Ther. 2007 Nov 19; 49(1274):93-4
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US population. The prevalence appears to be lower in non-whites.
Topotecan hydrochloride ( Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer…
Med Lett Drugs Ther. 1996 Oct 25; 38(986):96-7
Topotecan hydrochloride ( Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin ( Platinol ) or carboplatin ( Paraplatin ) plus paclitaxel ( Taxol ) or cyclophosphamide ( Cytoxan , and others).